Direct Measurement of Semaglutide's Impact on Eating Behavior in Obesity

Obesity is a complex metabolic disease with significant health implications, often linked to dysfunctional eating patterns. While GLP-1 receptor agonists (GLP-1 RAs) like semaglutide are highly effective for weight loss, their precise impact on the microstructure of human eating behavior and food selection has largely been inferred from indirect measures like questionnaires. This study addresses the critical necessity to directly measure changes in ingestive behavior after GLP-1 RA treatment to gain objective insights.

As an active, not yet recruiting study, specific findings are not available, but the primary hypothesis is that semaglutide treatment will significantly alter the microstructure of ingestive behavior. Researchers anticipate observing specific, quantifiable patterns in food selection and intake that can be used for behavioral phenotyping. This direct measurement is expected to provide more objective data than previous indirect assessments. The study aims to directly quantify changes in meal size, eating rate, and food choices, expecting a significant reduction in overall caloric intake and a shift towards healthier food preferences in the treatment group compared to controls. These insights could reveal novel mechanisms of GLP-1 RA efficacy beyond simple appetite suppression, offering a deeper understanding of how these drugs influence eating habits.